Tevogen bio leverages microsoft partnership to deliver machine learning based target identification to address human papilloma virus (hpv), advancing tvgn 920

Warren, n.j., nov. 05, 2024 (globe newswire) -- tevogen bio (“tevogen” or “tevogen bio holdings inc.”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t cell therapeutics to treat infectious disease and cancers, recently announced its artificial intelligence effort, tevogen.ai, had partnered with microsoft (nasdaq: msft), the world's leading ai company.
MSFT Ratings Summary
MSFT Quant Ranking